Balancing efficacy and toxicity in the treatment of childhood ALL
EHA Library. Vora A. 06/14/17; 185016
Topic: 3Fa Acute lymphoblastic leukemia (B or T)
Prof. Dr. Ajay Vora
Contributions
Contributions
Learning Objectives
Rob Pieters - Chair Introduction
In this session, three experts will discuss current important topics that gain a lot of interest in the word of acute lymphoblastic leukemia. First, overall survival for childhood ALL has increased from zero to 90% over the last 6 decades by intensifying therapy for all of them. It becomes important to identify the cases with a survival chance of close to 100% and to study whether therapy can be reduced in these. Second, several immunotherapeutic modalities for treatment of ALL have emerged in the last decade. Most promising are different types of antibodies and most recently the use of CAR-T cells genetically engineered to attack CD19 and other B-cell antigens. Infusion of CAR-T cells results in very high rates of molecular remissions. Not only the successes but also the limitations and treatment failures will be discussed. Third, although the number of new drugs approved for its use in ALL is limited, there is a large pipeline of drugs and immunotherapeutic strategies that are highly promising. These are mainly based on new knowledge of molecular-genetic abnormalities such as the bcr-abl like subtype. The status of these new therapeutic modalities will be discussed.
Learning Objectives of the manuscript
After viewing this presentation the participant will be able to:
- To learn in which ALL patients therapy can be reduced and how this can be done
- To learn about the successes and also the limitations and failures of CAR-T cells in ALL
- To learn about the new therapeutic strategies largely based on molecular genetic abnormalities in ALL
Learning Objectives of the presentation
After viewing this presentation the participant will be able to:
- Describe the burden of toxicity of treatment for childhood ALL.
- Discuss risk stratification for childhood ALL.
- Select treatment that provides optimal efficacy with minimal toxicity based on leukaemia phenotype, genotype and treatment response.
In this session, three experts will discuss current important topics that gain a lot of interest in the word of acute lymphoblastic leukemia. First, overall survival for childhood ALL has increased from zero to 90% over the last 6 decades by intensifying therapy for all of them. It becomes important to identify the cases with a survival chance of close to 100% and to study whether therapy can be reduced in these. Second, several immunotherapeutic modalities for treatment of ALL have emerged in the last decade. Most promising are different types of antibodies and most recently the use of CAR-T cells genetically engineered to attack CD19 and other B-cell antigens. Infusion of CAR-T cells results in very high rates of molecular remissions. Not only the successes but also the limitations and treatment failures will be discussed. Third, although the number of new drugs approved for its use in ALL is limited, there is a large pipeline of drugs and immunotherapeutic strategies that are highly promising. These are mainly based on new knowledge of molecular-genetic abnormalities such as the bcr-abl like subtype. The status of these new therapeutic modalities will be discussed.
Learning Objectives of the manuscript
After viewing this presentation the participant will be able to:
- To learn in which ALL patients therapy can be reduced and how this can be done
- To learn about the successes and also the limitations and failures of CAR-T cells in ALL
- To learn about the new therapeutic strategies largely based on molecular genetic abnormalities in ALL
Learning Objectives of the presentation
After viewing this presentation the participant will be able to:
- Describe the burden of toxicity of treatment for childhood ALL.
- Discuss risk stratification for childhood ALL.
- Select treatment that provides optimal efficacy with minimal toxicity based on leukaemia phenotype, genotype and treatment response.
{{ help_message }}
{{filter}}